Impel Neuropharma Inc (IMPL) USD0.001
Impel NeuroPharma, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system (CNS). The Company offers Precision Olfactory Delivery (POD), which is a upper nasal delivery technology with well-established therapeutics or other therapeutics where vascular absorption is preferred to drive therapeutic benefit, improve patient outcomes, reduce drug development risk and expand the commercial opportunity within its target diseases. The Company’s product candidates TRUDHESATM (INP104) is developed for providing acute treatment of migraine and INP105 for the acute treatment of agitation and aggression in patients with Autism Spectrum Disorder (ASD). Its pipeline of proprietary product candidates also includes INP107 for the treatment of OFF episodes in Parkinson’s Disease.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.